BMO Capital Starts Teva Pharma (TEVA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to BMO Capital Starts Teva Pharma (TEVA) at Outperform
July 27, 2015 4:47 AM EDT
$4.97 Billion in Revenue and $1.43 in Non-GAAP EPS
Raises 2015 EPS Guidance
JERUSALEM--(BUSINESS WIRE)--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced
preliminary financial results for the second quarter of 2015:
Revenues of approximately $4.97 billion, down 2% compared to the
second quarter of 2014. Excluding the impact of foreign exchange
fluctuations and the sale of U.S. OTC plants in July 2014, revenues
increased 6% compared to the second quarter of 2014.
Non-GAAP diluted earnings per share (EPS) of $1.43 in the...
More
July 27, 2015 4:31 AM EDT
JERUSALEM--(BUSINESS WIRE)--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that it has withdrawn its cash and stock proposal to acquire
all of the outstanding ordinary shares of Mylan N.V. (NASDAQ: MYL) and
Teva does not intend to continue to pursue a transaction with Mylan at
this time. Tevas decision to terminate the proposal to acquire Mylan
follows todays announcement that Teva has entered into a definitive
agreement with Allergan to acquire Allergan Generics.
In light of our strategic acquisition of Allergan... More
July 27, 2015 4:30 AM EDT
Acquisition Strongly Reinforces Teva's Strategy, Accelerates the
Creation of Its New Business Model and Opens a New Set of Possibilities
for the Company In Generics and Specialty
Opportunity to Further Transform the Global Generics Space through
Best-In-Class Generics Pipeline, R&D Capabilities, Operational Network,
Supply Chain, Global Commercial Deployment and Infrastructure
Robust Generics Platform to Support Future Strategic Investment in
Specialty
Teva Will Be a Top 10 Global Pharmaceutical Company
Enhanced Financial Profile with Strong, Diversified Revenues
... More
